Status:

COMPLETED

The Assessment of the Diagnosis and Prognosis of Patients With Alzheimer Disease or Parkinson Disease With Cognitive Impairment by Using Diffusion MRI

Lead Sponsor:

Chang Gung Memorial Hospital

Conditions:

Alzheimer Disease

Parkinson Disease

Eligibility:

All Genders

50-80 years

Brief Summary

The hypothesis is that the differential extent of microstructural damages in the affected brain regions can be specific to the disease of interest and could reflect the clinical severity. Therefore, t...

Detailed Description

Currently, Alzheimer's Disease (AD) and Parkinson's Disease (PD) are diagnosed mainly by neurologists, based on clinical symptoms. However, there are no objective criteria available for their diagnosi...

Eligibility Criteria

Inclusion

  • All subjects should meet the following criteria:
  • Between 50-80 years old
  • Right-handed
  • Able to understand study requirements and give informed consent
  • Agree to return for follow-up checks
  • Able to suspend intake of medication for at least 12 hours

Exclusion

  • Cardiac pacemaker or defibrillator implantation Intracranial metal device implantation
  • Other major systemic diseases, such as renal failure, heart failure, stroke, AMI/unstable angina, poorly controlled diabetes mellitus, poorly controlled hypertension
  • Alcohol or drug abuse
  • Moderate to severe dementia
  • Severe movement disorders
  • Imaging data is similar to a nuclear medical examination, exclusion criteria is any abnormality that may affect cognitive function as reflected in computer tomography or MRI records, such as hydrocephalus or encephalitis. Mild cortical atrophy is acceptable.
  • History of intracranial surgery including thalamotomy, pallidotomy, and/or deep brain stimulation
  • Major physical or neuropsychiatric disorders
  • Structural abnormalities that may cause dementia, such as cortical infarction, tumour, or subdural hematoma
  • Besides medication for Parkinson's Disease, taking other medication with substances that can pass through the blood-brain barrier
  • Besides medication for Parkinson's Disease, taking other medication for more than 10 years
  • Treatments or concurrent illnesses other than Alzheimer's Disease that could interfere with cognitive function
  • Meet the criteria for dementia (DSM-IV)
  • Head trauma with loss of consciousness greater than 10 minutes
  • Severe loss of sensation

Key Trial Info

Start Date :

October 1 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 30 2020

Estimated Enrollment :

212 Patients enrolled

Trial Details

Trial ID

NCT04434898

Start Date

October 1 2017

End Date

September 30 2020

Last Update

August 6 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

ChangGung Memorial Hospital, Linkou

Taoyuan District, Taiwan, 333

The Assessment of the Diagnosis and Prognosis of Patients With Alzheimer Disease or Parkinson Disease With Cognitive Impairment by Using Diffusion MRI | DecenTrialz